



U.S Department of Justice

Drug Enforcement Administration


Drug Enforcement Administration

800 K Street, N.W., Suite 500

Washington, DC 20001

+1 (202) 601-5541

May 15th, 2025



RE: Ongoing Investigation – NPI No. 1932102985– Case No. RS95873

Dear Dr. [REDACTED]

This letter serves as formal notification that the Drug Enforcement Administration (DEA), in coordination with federal and international enforcement partners, is conducting an active investigation involving your DEA registration and National Provider Identifier (NPI) number.

Our investigation has uncovered substantial evidence linking your DEA license and prescribing credentials to controlled substances originating from South America that were unlawfully distributed within the United States. Preliminary findings indicate that multiple shipments of Schedule II and Schedule III controlled medications—specifically opioids and stimulants—have been traced back to prescriptions electronically attributed to your name and identifiers.

Furthermore, several of these prescriptions appear to lack legitimate medical purpose, fall outside your documented scope of practice, and were issued to

individuals who have no verifiable clinical association with your practice. These actions may constitute serious violations of the Controlled Substances Act (21 U.S.C. § 801 et seq.) and may also implicate violations of federal anti-diversion and healthcare fraud statutes.

As part of our investigation, we will be initiating the following:

1. Immediate administrative inspection of your practice under 21 U.S.C. § 880.
2. Formal subpoena for records, including but not limited to:
 - Prescription logs
 - EPCS (Electronic Prescribing of Controlled Substances) access logs
 - Inventory and dispensing records
3. Verification of compliance with DEA recordkeeping and security regulations as outlined in 21 C.F.R. §§ 1304, 1305, and 1306.

You are hereby advised to preserve all records, both electronic and physical, pending further investigation. Alteration, destruction, or concealment of evidence may result in obstruction charges.

You may be accompanied by legal counsel during any interviews or inspections. Failure to cooperate may result in the suspension or revocation of your DEA registration, civil penalties, and potential criminal prosecution.

If you have reason to believe your credentials were used without authorization, we urge you to report the incident in writing and provide all supporting documentation at your earliest convenience.

If you have any questions about the interim, you may contact our general headquarters line (202) 601-5541 or Supervisory Diversion Investigator [Danny D. Watson] at (202)-860-2008.

Sincerely,

Danny D. Watson

Special Agent, Diversion Control Division

U.S. Drug Enforcement Administration

Washington D.C